CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Indivior PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Indivior PLC
10710 Midlothian Turnpike
Suite 125, North Chesterfield
Phone: 804-3791090p:804-3791090 CHESTERFIELD, VA  23235  United States Ticker: INDVINDV
Business Summary
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8741 Management services
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board David E.Wheadon 67 1/28/2025 6/1/2024
Chief Executive Officer Joseph J.Ciaffoni 53 5/1/2025 12/17/2024
Chief Human Resource Officer JonFogle
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Indivior Finance S.ar.l. Luxembourg
RBP Global Holdings, Ltd. 103-105 Bath Road Berkshire United Kingdom
Indivior plc United Kingdom
Opiant Pharmaceuticals Inc 233 Wilshire Blvd, Suite 400 SANTA MONICA CA United States

Business Names
Business Name
A12FHW
Bio-Found Limited
Indivior (Beijing) Pharmaceuticals Information Consulting Co. Ltd
72 additional Business Names available in full report.

General Information
Number of Employees: 1,030 (As of 12/31/2024)
Outstanding Shares: 124,769,533 (As of 5/1/2025)
Shareholders: 1,027
Stock Exchange: LON


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, May 13, 2025